OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS
PSYCH: What are the next steps
for investors?
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
Substance Use
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS AND INSIGHTS
Results of Major Study on Impact of Microdosing Published
Researchers from Imperial College London have carried out the largest placebo-controlled trial into psychedelics to date and found that small doses of LSD boost the psychology of users in a manner of ways. However, when the researchers examined what trial volunteers took, they found placebos worked equally as well as the drug. In short, theContinue reading
An Analysis of Microdosing Psychedelics
During The PSYCH Symposium in November 2020, a panel of leading scientists discussed their work in the field of psychedelic medicines as well as the research they had conducted on microdosing and the impact it has on the human body. Does it increase creativity? Improve focus or nothing more than a silicon valley fad? FindContinue reading
When Mother Nature Becomes Big Business
During The PSYCH Symposium in November 2020, a panel of leading experts operating in psychedelics sector, discussed the cultural challenge of commercialising the likes of psilocybin, DMT and LSD. This discussion, featuring a number of leading voices from across the psychedelics spectrum, focused on the problems which may arise as a result of removing theContinue reading
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
ISSUES
Issue 17
The results of a study on the use of MDMA to treat alcohol addiction have been published this week, whilst reforms on the use of psychedelics continue to take shape across the US.
Issue 18
Researchers have published the results on the most comprehensive study on microdosing while European psychedelic companies have been given an edge in the international market.
